INHIBITORS
-
Novel treatments in bleeding disorders: The European Haemophilia Consortium Review
CLICK HERE to access the June 2021 review of novel treatments in haemophilia and other bleeding disorders by the European Haemophilia Consortium.
-
CHS 5-year strategic framework officially launched!
The CHS is pleased to share its brand new five-year strategic framework following an extensive strategic planning exercise held in 2020. The strategy is expressed...
-
CBS recommends emicizumab (Hemlibra) to Ministers of Health
On May 25, 2021, Canadian Blood Services (CBS) released its recommendation on emicizumab (Hemlibra) to the provincial/territorial Ministers of Health. CBS recommends that emicizumab be listed...
-
Coagulation products | Current and in the pipeline
Updated charts for products in the pipeline have been uploaded on the CHS website. The CHS publishes four charts, one each for clotting factor concentrates,...
-
Community awaits decisions on access to Hemlibra
Montreal, February 4, 2021 – The hemophilia community is awaiting decisions by Canadian health authorities on access to Hemlibra for people with hemophilia A without...